Patiromer vs Placebo to Enable Spironolactone Use in Patients With Resistant Hypertension and Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patiromer Versus Placebo to Enable Spironolactone Use in Patients With Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 2019 Sep 13;[EPub Ahead of Print], R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo, S Warren, J Ma, WB White, B WilliamsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.